Low selectivity index of ivermectin and macrocyclic lactones on SARS-CoV2 replication in vitro argues against their therapeutic use for COVID-19.

Christine Chable-Bessia^{1*}, Charlotte Boullé^{2,3*}, Aymeric Neyret¹, Jitandrya Swain⁴, Mathilde Hénaut¹, Peggy Merida⁴, Nathalie Gros¹, Alain Makinson^{2,3}, Sébastien Lyonnais¹, Cédric B. Chesnais^{2,3\$}, and Delphine Muriaux^{1,4\$}

Affiliations

¹ CEMIPAI, Montpellier University, UAR3725 CNRS, Montpellier, France

² TransVIHMI, Montpellier University, Institut de Recherche pour le Développement (IRD) Unité Mixte Internationale 233, INSERM Unité 1175, Montpellier, France

³ Infectious Disease Department, University Hospital of Montpellier, Montpellier, France

⁴ Institute of Research in Infectiology of Montpellier (IRIM), University of Montpellier, UMR9004 CNRS, Montpellier, France

*Contributed equally to this work

\$Corresponding author: delphine.muriaux@irim.cnrs.fr

\$Alternative corresponding author: cedric.chesnais@ird.fr

Abstract

There are very limited antiviral therapeutic options for coronavirus infections, therefore global drug re-purposing efforts are paramount to identify available compounds that could provide clinical benefits to patients with COVID-19. Ivermectin was first approved for human use as an endectocide in the 1980s. It remains one of the most important global health medicines in history and has recently been shown to exert *in vitro* activity against SARS-CoV-2. However, the macrocyclic lactone family of compounds has not previously been evaluated for activity against SARS-CoV-2. The present study aims at comparing their anti-viral activity in relevant pulmonary cell lines *in vitro*. Here, *in vitro* antiviral activity of the avermectins (ivermectin and selamectin) and milbemycins (moxidectin and milbemycin oxime) were assessed against a clinical isolate from a CHU Montpellier patient infected with SARS-CoV-2 in 2020. Ivermectin demonstrated anti-SARS-CoV-2 activity *in vitro* in human pulmonary cells in comparison to VeroE6 (with EC₅₀ of 1-3 µM). Similarly, the other macrocyclic lactones moxidectin, milbemycin oxime and selamectin reduced SARS-CoV-2 replication *in vitro* (with EC₅₀ of 2-5 µM). Immunofluorescence assays with ivermectin and moxidectin showed a reduction in the number of infected and polynuclear cells suggesting a drug action on viral cell fusion. However, cellular toxicity of the avermectins and milbemycins during infection showed a very low selectivity index <10 for all compounds. In conclusion, none of these agents appears suitable for human use for its anti-SARS-CoV-2 activity *per se*, due to low selectivity index. This is discussed in regards to recent clinical COVID studies on ivermectin.

Key words: SARS-CoV-2; *in vitro* drug screening; ivermectin, anti-parasite drugs, antiviral specificity index.

Introduction

In December 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in Wuhan, China [1,2]. SARS-CoV-2 is a beta-coronavirus, which are enveloped viruses containing single-strand, positive-sense RNA. No effective treatment or treatment regimen has been established for coronavirus disease-2019 (COVID-19) to date and although success has been achieved with vaccination modalities, there remains a need for therapeutic approaches for the unvaccinated and for vaccine escape mutants. Screening existing, regulatory approved medicines for potential activity against SARS-CoV-2 offers the potential to reduce unnecessary animal and clinical evaluations. Repurposing requires comprehensive understanding of the pharmacokinetic/pharmacodynamic relationship of the product and changes from the approved posology result in potentially significant data generation requirements. Several candidates have emerged from this strategy although a convincing antiviral therapy has yet to emerge. The directly antiviral remdesivir has conflicting efficacy data, and lopinavir/ritonavir, hydroxychloroquine and ivermectin have been successively ruled out in randomized clinical trials [3–6]. Dexamethasone for oxygen-requiring patients has evidence of clinically-relevant efficacy in the RECOVERY trial [7], through reduction of the inflammatory response in the latter phase of the infection. Therefore, the therapeutic arsenal is still limited and further options are needed.

Ivermectin (IVM) is a widely used antiparasitic drug targeting the gamma aminobutyric acid and glutamate-gated chlorine channel in invertebrates, causing flaccid paralysis of parasite and becoming one of the world's most important global health medicines, a discovery awarded a Nobel prize in 2015. Apart from its antiparasitic effect against filariae and ectoparasites, there is evidence of anti-inflammatory and antiviral properties on RNA-viruses, mostly of the flaviviridae family (including dengue (DENV), zika, yellow fever) [8]. A study by Caly et al [9] reported that IVM inhibited SARS-CoV-2 in vitro using the Vero-hSLAM assay. However, the concentration

resulting in 50% inhibition (IC₅₀, 2 to 2.5 μ M i.e. 1750 to 2,190 ng/mL) was several times higher than the maximal plasma concentration (C_{max}) that can be reached after the oral administration of the FDA approved dose for onchocerciasis (200 μ g/kg e.g. 14 mg for 70 kg) [10–12] Human lung exposure is thought to reach a maximum of 772 ng/mL [13]. IVM doses up to 120 mg have been administered and appeared well tolerated, but with limited experience; the *in vitro* IC₅₀ by Caly et al was > 9-fold and > 21-fold higher than the day 3 plasma and lung tissue simulated C_{max} respectively, following a higher dose IV regimen of 600 μ g/kg dose daily for 3 days. This dose scenario exceeds the highest regulatory approved dose of IVM of 200 μ g/kg single dose for the treatment of strongyloidiasis.

IVM is generally well tolerated [14], except for potential neurotoxicity that could be linked to GABA-gated channel in the central nervous system of mammals if the blood-brain barrier (BBB) integrity is damaged, a possible mechanism of COVID-19 encephalopathy during the cytokinic storm. This neurotoxicity is enhanced in case of mutations of the P-glycoprotein (P-gp), one of the main BBB efflux-pump, for which IVM is a substrate.

Put together, these results highlight the importance of pharmacokinetic considerations, acknowledging that discrepancies between *in vitro* and *in vivo* results have been observed. For instance, DNV's (dengue virus) IC₅₀ is even higher (17 μ M) [15].

SARS-CoV-2 enters host cells by binding to angiotensin-converting enzyme 2 (ACE2) receptors, widely distributed in human tissue but predominantly in human alveolar epithelial cells [16,17] Mechanisms underlying the possible antiviral effect of IVM include its ability to bind to the host's importin (IMP) α leading to dissociation of the IMP α/β 1 heterodimer and modifying the interaction of IMP with viral proteins therefore hampering nuclear import [18,19]. Other hypothesis include allosteric modulation of the α 7 nicotinic acetylcholine receptor (nAChR) [20,21].

IVM belongs to the wider family of macrocyclic lactones, being synthesized through a semi-fermentation pathway through bacteria of the *Streptomyces* genus. The macrocyclic lactones are divided into two classes: avermectins (ivermectin, doramectin, selamectin) and milbemycins (moxidectin and milbemycin oxime) depending on the substitution at the position 13 of the macrolide ring, also common to macrolide antibiotics (also investigated as potential antiviral molecules in SARS-CoV-2 infection). IVM and moxidectin (MOX, achieved FDA-approval for onchocerciasis [22–24]) are the only macrocyclic lactones approved for human use by a regulatory authority, while selamectin, doramectin and milbemycin oxime are approved for veterinary use only. Similarities across these drugs include mode of action and lipophilic properties leading to preferential deposition in adipose tissues, but they differ in the degree they are substrates for transporters, GABA and glutamate gated chloride channel binding, and their respective absorption, distribution, metabolism and excretion (ADME) profiles. Moxidectin's human elimination half time ($t_{1/2}$) reaching > 20 days following oral administration [25,26]. MOX is also a weak substrate of P-gp, and has demonstrated lower neurotoxicity in models of neurotoxicosis.

To explore the potential of this class of compounds against SARS-CoV-2, we screened avermectins and milbemycins for their antiviral efficacy *in vitro*.

Materials and methods

Cell lines and culture

Vero E6 cells (African green monkey kidney cells) were obtained from ECACC and maintained in Dulbecco's minimal essential medium (DMEM) supplemented with 10% heat inactivated fetal bovine serum (FBS) 50 U/mL of penicillin, 50µg/mL of streptomycin, 25mM of HEPES at 37°C with 5% CO₂. The human pulmonary alveolar A549-hACE2 cells were engineered using a lentiviral vector from Flash Therapeutics (Toulouse, France) to express the human receptor ACE2.

A549 cells obtained from ECACC(#86012804) were transduced and maintained in RPMI supplemented with 10% heat inactivated fetal bovine serum (FBS), 50 U/mL of penicillin, 50 µg/mL of streptomycin, 25mM of HEPES and 1mM of sodium pyruvate at 37°C with 5% CO₂. Cells were then sorted by FACS in order to obtain a A549-hACE2 population stably expressing hACE2. Calu-3 cells (epithelial lung adenocarcinoma cells) were obtained from Elabscience (#EP-CL-0054) and maintained in DMEM supplemented with 10% heat inactivated FBS, 50 U/mL of penicillin, 50µg/mL of streptomycin, 25 mM of HEPES at 37°C with 5% CO₂.

SARS-CoV-2 virus

SARS-CoV-2/CHU Montpellier/France was isolated from CPP Ile de France III, n°2020-A00935–34 and “Centre de Ressources Biologiques” collection of the University Hospital of Montpellier (France). The virus was propagated in VeroE6 cells with DMEM containing 2.5% FBS, 25 mM HEPES at 37°C with 5% CO₂ and was harvested 72 hours post inoculation. Virus stocks were stored at -80°C. All work with infectious SARS-CoV-2 was performed in an approved biosafety level 3 (BSL3) facility by trained personnel at the CEMIPAI UAR3725.

Virus titration

Virus titration from infected cell culture supernatant were monitored using plaque assays on a monolayer of VeroE6 cells. Briefly, Vero E6 cells were inoculated with 10-fold serial dilutions (10^{-1} , 10^{-2} , 10^{-3} , 10^{-4} , 10^{-5}) of a SARS-CoV-2 stock and incubated for one hour at 37°C with regular rocking. Inoculum was removed and replaced with 500µL/well of agar overlay (MEM; 0.1% sodium bicarbonate, 0.2% BSA, 20 mM HEPES, 0.6% oxoid agar). Once the overlay had solidified, plates were incubated at 37°C for 72 h prior to fixing with 4% PFA and staining with crystal violet to visualize plaques. Plaques were quantified and viral titer of the stock sample was determined as plaque-forming units (PFU)/mL, by taking the average number of plaques for a dilution and the inverse of the total dilution factor.

Assessment of antiviral activity

Drugs were purchased from Sigma Aldrich: moxidectin (#Y0000772), doramectin (#33993), milbemycin oxime (#Y0001893), selamectin (#Y0000814), ivermectin (#I8000010). Drug structures are presented in Figure 1A. Remdesivir (#282T7766) was purchase from Tebu. Drugs were prepared at a concentration of 10 mM in DMSO.

Antiviral activity was assessed by cytopathic effect (CPE) reduction assay on Vero E6 cells or by RT-qPCR on A549-hACE2 or Calu-3 cells. Briefly, 30,000 cells per well were cultured in 96-well culture plates for 24 hours. Drugs were diluted from stock to 50 μ M in DMEM or 25 μ M RPMI for testing antiviral activity on VeroE6 cells or A549-hACE2 cells, respectively. Cells were incubated with 100 μ L of the compounds diluted in DMEM / 0.5% DMSO (v/v) (Vero E6) or RPMI / 0.25% DMSO (A549hACE2) or DMEM / 0.25% DMSO (Calu-3) at the indicated concentrations and the plate were incubated for 2 hours. Subsequently, cells either were mock infected (for analysis of cytotoxicity of the compound) or were infected with 400 PFU of virus per well (MOI of 0.01) in a total volume of 110 μ L of medium with compound. Cell viability was assessed 3 days postinfection by MTS assay using a Cell Titer 96 aqueous cell proliferation kit (Promega) or Viral ToxGlo™ (ToxGlo assay). Absorption at 495 nm (MTS) or luminescence (ToxGlow) were measured with an EnVision multilabel plate reader (PerkinElmer). The 50% effective concentration (EC₅₀ [the concentration required to inhibit virus-induced cell death by 50%]) and the 50% cytotoxic concentration (CC₅₀) (the concentration that reduces the viability of uninfected cells to 50% of that of untreated control cells) were determined using 4-parameter nonlinear regression with GraphPad Prism v8.0, based on the following calculations:

$$\text{Cell cytotoxicity, \%TOX} = (1 - \frac{\text{drug}}{\text{cell DMSO}}) \times 100$$

$$\text{Percentage of viral replication inhibition, \%Inhibit} = (\frac{\text{drug-infected cells}}{\text{cell DMSO-infected cells}}) \times 100$$

Data are mean $\pm$ sd of three biological replicates, each of which consisted of duplicate samples. Data were normalized as the relative efficiency or cell viability of inhibitor-treated cells compared with those of untreated cells (set to 100%).

Quantitative reverse transcription polymerase chain reaction (RT-qPCR)

Viral particles were collected from virus-infected A549 hACE2 cell supernatants at 72 hours post infection (100 μ L) and viral RNAs were isolated from the supernatants using the Quick RNA Viral 96 Kit (Zymo Research) according to the manufacturer's instructions. Viral RNAs were isolated from Calu-3 infected cells 48h post infection using the Luna Cell Ready Lysis Module (New England Biolabs). Viral RNA were quantified by qRT-PCR in triplicate as described in [27], using primers targeting the E gene of SARS-CoV-2 (E_Sarbeco ACAGGTACGTTAATAGTTAATAGCGT; E_Sarbeco-R ATATTGCAGCAGTACGCACACA) and Luna Universal One-Step qRT-PCR Kit (New England Biolabs) on a Roche Light Cycler 480. The calibration of the assay was performed with a nCoV-E-Sarbeco-Control Plasmid (Eurofins Genomics).

Immunofluorescence and confocal microscopy infected cell imaging

A549-hACE2 cells seeded on glass coverslips were infected with SARS-CoV-2 at a MOI 0.01. At 45 hours post-infection, cells were washed with PBS and fixed in 4% paraformaldehyde in PBS for 15 minutes at room temperature, followed by permeabilization with 0.2% Triton X-100 in PBS for 4 to 5 minutes and blocking in 2% BSA in PBS for 15 min. Cell supernatants for each condition were used for virus quantification by RT-qPCR. Incubation with primary antibodies anti-SARS-CoV-2 rabbit membrane (M) protein (Rockland) (1:100) was performed for 2 hours at room temperature. After washing with PBS, cells were incubated with secondary antibodies AF568-labeled goat-anti-rabbit (Invitrogen) (1:1000) for 2 hours at room temperature. The coverslip were sealed with Prolong Diamond Antifade reagent (Fisher Scientific). Epifluorescence and confocal

fluorescence images were generated using a Cell-Discoverer 7 LMS900 confocal laser-scanning microscope (Zeiss). DAPI-stained nuclei surfaces were analyzed using ZEN software (Otsu threshold method) from a grid of 8x8 images taken at 20x magnification. The percentage of polynuclei cells were quantified manually for a total of 1000-1200 cells. For intensity analysis, cells were imaged as Z stack with 0.3 μm sections then Z projection images were processed for total intensity per cell using ImageJ/Fiji. Statistical tests were performed using Origin 8.5 software. Statistical significance was evaluated using one-way ANOVA tests. $**p < 0.05$.

Results

In vitro antiviral activity of avermectins or milbemycins in simian VeroE6 cells

To determine if avermectins or milbemycins could protect cells from SARS-CoV-2 infection and to evaluate their toxicity, a cytopathic effect (CPE) reduction assay was first performed on African green monkey kidney-derived cell line Vero E6, which present an ACE2 receptor and are widely used as infection models for SARS-CoV-2 and for antiviral screening. We compared two commercial assays for determining cell viability, both based on quantitation of cellular metabolism; i.e. an MTS assay and ToxGlo assay (Figure S1). Vero E6 cells were pretreated with serial dilutions of the drugs, then infected with SARS-CoV-2, and were kept in the medium with compounds for 72 hours. Table 1 and Figure 1B recapitulate the main features of the evaluated compounds, including the dose-response curves for both assays and estimation of the 50% cytotoxic concentration (CC50).

As expected from previous studies [28,29], calculated EC50 values for our positive control, remdesivir, were in the low micromolar range ($\text{EC}_{50 \text{ REM MTS}} = 0.55 \mu\text{M}$ and $\text{EC}_{50 \text{ REM TOXGLO}} = 1.02 \mu\text{M}$). Remdesivir showed a very favorable selectivity index (SI) (> 50 with MTS, > 100 with ToxGlo), in agreement with previous reports [28,29]. We found that avermectins

and milbemycins protected infected cells from SARS-CoV-2-induced cell death in a dose-dependent manner (Figure 1B). Both MTS and ToxGlo assays provided similar results. The compounds however showed important toxicity, causing CC50 to drop to around 8 μ M with SI, which hindered the numerical treatment of the dose-response curves that lacked a clear plateau for the highest concentration. In addition, cell survival curves showed a reproducible increase for all the tested molecules in the 1 to 5 μ M range, before a dramatic drop in cell viability. Indeed, similar CC50 values have been reported for HeLa cells treated with IVM, which has been proposed to induce cell cycle arrest, apoptosis and autophagy, presumably through mitochondrial pathways [30,31].

This effect was not seen upon treatment with remdesivir. Nevertheless, EC50 could be broadly estimated from the data and showed antiviral activity for IVM with $EC_{50 \text{ IVM MTS}} = 3.6 \mu\text{M}$ and $EC_{50 \text{ IVM TOXGLO}} = 3 \mu\text{M}$, DOR with $EC_{50 \text{ DOR MTS}} = 2.4 \mu\text{M}$ and $EC_{50 \text{ DOR TOXGLO}} = 1.1 \mu\text{M}$, and SEL with $EC_{50 \text{ SEL MTS}} = 3.9 \mu\text{M}$ and $EC_{50 \text{ SEL TOXGLO}} = 2.3 \mu\text{M}$. MIL and MOX show antiviral activities within the same concentration range, with respectively $EC_{50 \text{ MIL MTS}} = 3.8 \mu\text{M}$ and $EC_{50 \text{ MIL TOXGLO}} = 2.6 \mu\text{M}$; $EC_{50 \text{ MOX MTS}} = 5.3 \mu\text{M}$ and $EC_{50 \text{ MOX TOXGLO}} = 3.5 \mu\text{M}$.

***In vitro* antiviral activity of IVM, MOX and MIL in human pulmonary alveolar A549-hACE2 cells**

To assess the antiviral effect of IVM, MOX and MIL in a more relevant model, human pulmonary alveolar A549 cells, expressing the human ACE2 receptor thanks to a selected A549-hACE2 cellular clone upon transduction with a hACE2-containing lentiviral vector, were infected with SARS-CoV-2, following the same procedure than with Vero E6 cells. Cell viability/CPE was measured with the MTS assay. Additionally, viral RNAs were isolated from cell supernatant 72 hours post-infection and quantified by RT-qPCR. Cytotoxicity assays were performed in parallel

in non-infected A549-hACE2 cells. The results are reported in Table 1 and Figure 2. Consistent with the data obtained with Vero E6 cells, we observed a strong dose-dependent reduction of infectivity and of the extracellular viral RNA levels in remdesivir-treated samples ($EC_{50 \text{ REM MTS}} = 0.15 \mu\text{M}$; $EC_{50 \text{ REM RTqPCR}} = 0.31 \mu\text{M}$), again associated with a low cytotoxicity. The $EC_{50 \text{ A549-hACE2}}$ for MOX, IVM and MIL were comparable both by MTS and by RT-qPCR and matched the EC_{50} measured in VeroE6 cells, in the range of $2 \mu\text{M}$. Cellular toxicity was similar for the three tested compounds, close to $\sim 6 \mu\text{M}$. MOX appeared as the best compound with an $EC_{50 \text{ MOX}} = 1.3$ and a SI slightly increased, from 1.6 in Vero E6 cells to 4.7 in A549hACE2 cells. In addition, the increase in cell proliferation was not seen in the A549-hACE2 cells. Together, these results suggest that IVM, MOX and MIL provide inhibitory effects against SARS-CoV-2 infection in human pulmonary cells, albeit associated with a poor selectivity.

***In vitro* antiviral activity of IVM, MOX and MIL in human bronchial Calu-3 cells**

The cellular response to virus infection can differ depending on the infected cell type, therefore we used the human bronchial epithelial Calu-3 cell lines, which express SARS-CoV-2 receptor ACE2 [32] and might better reflect physiological conditions than A549 cells ectopically expressing ACE2. In addition, Calu-3 cells, as with the airway epithelium, express low amounts of the cysteine protease cathepsin L (CTSL), which mediates SARS-CoV-2 entry into these cells by pH-independent pathway. By contrast, entry of SARS-CoV-2 into Vero cells is CTSL-dependent and thus uses a pH-dependent pathway [33]. As SARS-CoV-2 infection does not produce evident CPE when infecting the Calu-3 cells, we monitored virus replication upon drug addition by quantifying intracellular viral RNA by RT-qPCR. Toxicity of the compounds was evaluated by MTS assay. The results are reported in Figure 3 and Table 1. The control remdesivir was again found to be a potent SARS-CoV-2 inhibitor with $EC_{50} = 0.35 \mu\text{M}$ and a SI greater than 70. Interestingly, cell

viability was less affected upon incubation with IVM, MOX and MIL with CC50 estimated in the range of 22-26 μ M. Consequentially, the antiviral activity of the three compounds could be defined more precisely and raised $EC_{50} \text{ MOX} = 5.55 \mu\text{M}$ (SI = 4.7), $EC_{50} \text{ IVM} = 3.36 \mu\text{M}$ (SI = 5) and $EC_{50} \text{ MIL} = 6.8 \mu\text{M}$ (SI = 3.3). In summary, avermectins and milbemycins did efficiently block the infection of Calu-3 cells with SARS-CoV-2. The calculated EC_{50} were found in the same range than those found in Vero E6 and A549hACE2 cells, thus being cell-line independent, suggesting drug mechanistic effects that do not alter virus entry pathways [34].

***In vitro* activity of IVM and MOX on SARS-CoV2 shows a reduction in virus-induced cell syncytia**

We finally confirmed MOX and IVM antiviral activities by *in cellulo* monitoring in A549 hACE2 cells after 45 hours incubation in presence of 4 μ M of drugs (Figure 4A). The viral S/cellular ACE2 interaction has been shown to be responsible for the cell-cell fusion induced by SARS-CoV-2 infection [35]. As reported in Figure 4B, cell fusion was clearly visible in our assay using A549-hACE2 cells, where typical cells with multiple nuclei were detected using DAPI after infection with SARS-CoV-2. In contrast, non-significant cell fusion could be observed in non-infected cells (Figure 4C). We thus quantified the number of nuclei/cell (Figure 4C) or nucleus surface on a cell population in mock and infected cells; and compared the results with infected cells treated with 4 μ M IVM or 4 μ M MOX. Both results showed unambiguously a strong limitation of cell fusions in drug-treated cells, confirming the properties of IVM and MOX to reduce viral dissemination in cell culture.

We also monitored the SARS-CoV-2 infection level by immunofluorescence labelling SARS-CoV-2 M proteins. M is a transmembrane glycoprotein, one of the main structural protein of SARS-CoV-2 involved in particle formation and required for virion assembly [36–39]. M is found

associated with intracellular compartments, where fluorescence of an anti-M antibody was detected on membranes of infected cells, and endoplasmic Reticulum-related compartment (see Figure 4E). Quantification by confocal microscopy of M intensity per cell was used to compare virus production in infected and in IVM or MOX treated cells (Figure 4F) which showed a 2-3-fold decrease in the presence of MOX and IVM as compared to the wild-type. Overall, our results show that MOX and IVM interfere with virus induced cell syncytia and propagation *in vitro*.

Discussion

Antiviral activity

Using SARS-CoV-2 infected A549-hACE2 cells, we evidenced EC50 measured by RT-qPCR of 1.3 μ M, 2.4 μ M and 2.8 μ M for MOX, IVM, and MIL, respectively. These results were consistent with those obtained using Vero E6 cells where EC50 were ranging from 2.4 μ M (MTS) or 1.1 μ M (ToxGlo) for DOR to 5.3 μ M (MTS) or 3.5 μ M (ToxGlo) for MOX. These results were reproducible on bronchial epithelial cell culture (Calu-3) which is recognized as a classical model for studying human respiratory function [40].

We included IVM and remdesivir as control for our screening procedure to compare our result to previously published data. For IVM, we found similar EC50 (2.1-2.36 μ M on A549-hACE2 cells, 3-3.6 μ M on Vero E6 cells, 3.36 μ M on Calu-3 cells) to that reported by Caly *et al* (2 μ M). For remdesivir we also found similar EC50 (0.15-0.31 μ M) on A549-hACE2 cells, 0.55-1 μ M on Vero E6 cells, 0.35 μ M on Calu-3 cells) to that reported by Wang *et al* (0.77 μ M).

Impossibility to achieve pharmacokinetics/pharmacodynamic targets

Although IVM was thought to be a promising antiviral drug due to evidence of inhibition of SARS-CoV-2 replication *in vitro*, translating this activity *in vivo* is obviously subject to pharmacokinetics/pharmacodynamics issues, as recent apropos articles underlined. Repurposing

drugs need to be accompanied by evaluation of target plasma and lung concentrations following approved dosing in humans, for instance evaluating the lung $C_{\max}$:EC50. We chose this approach to provide estimates comparable to those by Arshad *et al*, that reviewed the largest panel of candidate molecules [41], although one has to keep in mind that it is overestimating the potency of drugs, that require EC90% to be lower than $C_{\min}$ to be truly qualifiable for further investigation.

MOX

In our study MOX EC50 was found to range between 1.3 and 5.55 μ M (equivalent to 832 – 3552 ng/mL or ng/g). As compared to IVM, higher $C_{\max}$ were generally observed for MOX, with studies showing $C_{\max}$ 70.4 ng/mL following 400 μ g/kg administration in horses [25] and as high as 234 ng/mL following 250 μ g/kg administration in dogs [26]. Nonetheless the observed $C_{\max}$ varies widely across studies with one study in sheep finding plasmatic $C_{\max}$ of 28 ng/mL following administration of MOX 0.2 mg/kg orally [42]. The study by Lifschitz et al, is to our knowledge the only one documenting lung distribution of MOX. The subcutaneous administration of MOX 200 μ g/kg to cattle (expected to lead to lower $C_{\max}$ as compared to the oral route) gave plasma $C_{\max}$ of 36 ng/g and lung $C_{\max}$ of 63.7 ng/mL, indicating a possible lung to plasma ratio around 2:1 for MOX distribution [43] .

Cotreau *et al*. conducted the first safety study of MOX in humans, as an ascending-dose study. In cohorts with higher doses, a slight increase in central neurological system grade 1-2 adverse events (nausea, vomiting, and somnolence) was noticed therefore the enrollment was closed before the planned 5 mg cohort, given that pharmacokinetics deemed the lowest posology for human use. Plasmatic $C_{\max}$ were found to be 141 ng/mL in the 18 mg cohort (~ 250 μ g/kg) and 289 ng/mL in the 36 mg cohort (~ 500 μ g/kg). Administration to subjects fed with high fat meal is thought to enhance $C_{\max}$ and AUC by > 1/3 when compared to fast subjects [44].

MOX has been FDA-approved for a single posology of 8 mg even though it is usually used in veterinary medicine at the posology of 200 µg/kg. The recent phase 3 clinical trial [24] used the 8 mg posology for subjects weighing 50 kg in average, resulting in a posology of 160 µg/kg and showed a good tolerance profile on the largest cohort so far (n=978 patients in the MOX group), as it had been shown in previous healthy volunteer studies [44–48].

Altogether, these data suggest that even optimistic hypothesis (posology of 36 mg, lung to plasma ratio 2:1, high-fat feeding x1.3) would still lead to expected lung $C_{max} < 750$ ng/mg after administration of 5x the currently approved dose, for a predicted lung C_{max}/EC_{50} ratio < 0.2 .

MIL, DOR and SEL

Very limited data on pharmacokinetics of other macrocyclic lactones (MIL, DOR and SEL) exist, mostly coming from isolated studies in animals.

SEL is exclusively used as a topical formulation of 6 mg/kg in cats and dogs, generally well tolerated [49]. Pharmacokinetic studies after IV (200 µg/kg) and oral (24 mg/kg) administration to cats/dogs showed plasma C_{max} of 874/636 ng/mL and 11929/7630 ng/mL, respectively, without raising any tolerance issue [50]. With an EC_{50} of 3.9 µM in our study (e.g. 3 000 ng/mL), the hypothesized plasma $C_{max}:EC_{50}$ $_{Vero-E6}$ for SEL at the posology of 24 mg/kg could therefore be close to 1.

DOR is used as an injectable form in ruminants, pigs and cattle, at the posology of 200 µg/kg and had equivalent plasma C_{max} 32-52 ng/mL in cattle and horse as compared to IVM. Terminal $t_{1/2}$ was ~ 5 days in both studies [51,52]. With an EC_{50} $_{Vero-E6}$ of 2.4 µM in our study (e.g. 2 158 ng/mL), the hypothesized plasma $C_{max}:EC_{50}$ $_{Vero-E6}$ for DOR at the posology of 200 µg/kg would therefore be ~ 0,02.

MIL is administered at the higher posology of 0.5 mg/kg in dogs and 2 mg/kg in cats for heartworm prevention. A mean C_{max} of 353 ng/mL following 920 µg/kg administration was observed in dogs

[53]. The lung to plasma ratio could also be around 2:1 as evidenced in rats in the original description of the drug by Ide *et al* [54]. With an $EC_{50_{A549-hACE2}}$ of 3.6 μM in our study (e.g. 1 998 ng/mL), the hypothesized plasma $C_{max}:EC_{50_{A549-hACE2}}$ for MIL at the posology of 920 $\mu g/kg$ would therefore be ~ 0.34 .

Toxicity

Along with encephalopathies following IVM administration in individuals with high *Loa loa* microfilaremia densities [55], the description of hypersensitivity reactions due to ABCB1 (formerly MDR1) mutations (encoding P-gp) following IVM administration has been recently evidenced [56]. This has been long known for animals, as those with P-gp gene defect experience such adverse events for doses reaching 5 to 10 mg/kg for MIL and for DOR. SEL has a greater margin of safety than IVM in P-gp mutated dogs [57–59]. MOX is minimally metabolized, has low affinity for P-gp [60] which might convert into a lower rate of adverse events, but still requires cautious attitude when considering wide use.

Mode of action

Immunofluorescence imaging showed less infected cells upon IVM or MOX treatment as shown by the antibodies labelling (infected red cells) as compared to the control, as well as restoration of cell shapes, suggesting the interference of IVM/MOX on viral replication complexes, directly or indirectly. Infected MOX/IVM treated cells showed an accumulation of the viral M proteins near or surrounding the nucleus (Figure 4). In addition, SARS-CoV-2 infected MOX/IVM treated cells present a reduction of S-dependent syncytia *in vitro* (Figure 4), suggesting a prevention of syncytia formation, by an unknown mechanism that could only be due to the reduction of viral replication. These results, although indirectly, are also compatible with a mechanism implying the ability of those drugs to bind to the importin (IMP) α hampering nuclear import [18,19], thus impairing viral

replication in general or by interfering with the SpikeRBD-hACE2 complex formation, as suggested by Lehrer S, Rheinstein PH (2020).

Limitations of this study

Our study is the first to examine antiviral parameters of macrocyclic lactones other than IVM on SARS-CoV-2, nevertheless the data we provide here are only *in vitro* data, and the recent developments encourage us to emphasize that they should therefore be taken cautiously, and that many steps are to be completed before any result can be translated into clinical practice. Clinical risk-benefit balance is not in favor of the use of any of these molecules at this early stage. In order to try to approach the pharmacokinetic parameters of the molecules concerned, we used the data available for avermectins and milbemycins, often obtained from animal data; which do not directly allow an extrapolation to humans. Nevertheless, the concordance of all the data suggesting the impossibility of reaching even an imperfect pharmacological target of $C_{max}:EC_{50}$ and therefore even less able to reach $C_{min}:EC_{90}$ seemed important to us to avoid inappropriate conclusions being reached drawn from these data.

Next steps and conclusion

Altogether our results clearly show that none of these agents is suitable for human use for its anti-SARS-CoV-2 activity *per se*. Our data show that DOR, MIL, and SEL are not clinically relevant candidates. They are not approved for human use, and therefore should not be used, and there is no rationale in our data to conduct the extensive studies that this would require (toxicology, impurity profile, thorough ADME evaluation).

Further steps could include *in silico* or *in vivo* studies, with the development of pharmacokinetic model to stimulate lung exposure to MOX similarly to what was done by Jermain *et al.* [13] for IVM, or the translation of this research towards animal models of SARS-CoV2 infection to detect if there could paradoxically be some *in vivo* efficacy even though pharmacokinetics profiles might

not be as favorable as those observed for remdesivir, despite this latter showing no clear clinical benefit, at least on mortality [61]. Interesting option may also lie in other routes of administration, if tolerated, to enhance local lung delivery, as the proof-of-concept study on nebulized IVM by Chaccour *et al.* investigated [62]. However, another just released study shows that in vitro cell culture of human primary airway epithelium, there is no inhibition of SARS-CoV2 replication reinforcing the idea that this drug might have no effect on virus replication in vivo [63].

Acknowledgements: We are grateful to Dr Edouard Tuaillon and Dr Vincent Foulongne for provision of the SARS-CoV-2 strain from the Centre de Ressources Biologiques collection of the University Hospital of Montpellier, France, and to Dr Moncef Benkirane (IGF, Montpellier, France) for providing the first amplification of this virus on Vero E6 cells. We are grateful to Dr Inès Arfa for initial provision of MOX from Elanco Pharmaceutical Compagny. JS is a recipient of an Infectiopole fellowship. This study was supported by the CNRS and Montpellier University through a Montpellier Université d'Excellence (MUSE) support, the IRD (UMI233 TransVIHMI), and the French Agency for Research (ANR COVID19).

Author contributions: CCB set up the assays and performed infections and antiviral assays; MH and NG performed cell culture, produced viral stocks; PM established the A549-hACE2 cell line; CCB and SL performed data analysis and calculations; AN performed RT-qPCR and analysis; JS performed the immunofluorescence sample preparation, confocal microscopy image acquisitions; JS and SL performed image analysis; SL, CCB and DM edited the figures; CB, SL, CCB, CC and DM wrote the manuscript; CB and CBC proposed the screening of avermectins and milbemycins family's molecules; DM raised funding and directed the study with CB and CC; All authors have read, edited the manuscript, and approved the final version.

Competing Interests: The authors have no competing interests.

References

1. Wu F, Zhao S, Yu B, et al. A new coronavirus associated with human respiratory disease in China. *Nature* **2020**; 579:265–269.
2. Zhou P, Yang X-L, Wang X-G, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. *Nature* **2020**; 579:270–273.
3. Cao B, Wang Y, Wen D, et al. A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19. *N Engl J Med* **2020**; 382:1787–1799.
4. The RECOVERY Collaborative Group. Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19. *N Engl J Med* **2020**; 383:2030–2040.
5. Self WH, Semler MW, Leither LM, et al. Effect of Hydroxychloroquine on Clinical Status at 14 Days in Hospitalized Patients With COVID-19: A Randomized Clinical Trial. *JAMA* **2020**; 324:2165.
6. López-Medina E, López P, Hurtado IC, et al. Effect of Ivermectin on Time to Resolution of Symptoms Among Adults With Mild COVID-19: A Randomized Clinical Trial. *JAMA* **2021**; 325:1426.
7. The RECOVERY Collaborative Group. Dexamethasone in Hospitalized Patients with Covid-19 — Preliminary Report. *N Engl J Med* **2020**; :NEJMoa2021436.
8. Heidary F, Gharebaghi R. Ivermectin: a systematic review from antiviral effects to COVID-19 complementary regimen. *J Antibiot* **2020**; 73:593–602.

9. Caly L, Druce JD, Catton MG, Jans DA, Wagstaff KM. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. *Antiviral Res* **2020**; 178:104787.
10. Schmith VD, Zhou JJ, Lohmer LRL. The Approved Dose of Ivermectin Alone is not the Ideal Dose for the Treatment of COVID-19. *Clin Pharmacol Ther* **2020**; 108:762–765.
11. Chaccour C, Hammann F, Ramón-García S, Rabinovich NR. Ivermectin and COVID-19: Keeping Rigor in Times of Urgency. *Am J Trop Med Hyg* **2020**; 102:1156–1157.
12. Bray M, Rayner C, Noël F, Jans D, Wagstaff K. Ivermectin and COVID-19: A report in Antiviral Research, widespread interest, an FDA warning, two letters to the editor and the authors' responses. *Antiviral Research* **2020**; 178:104805.
13. Jermain B, Hanafin PO, Cao Y, Lifschitz A, Lanusse C, Rao GG. Development of a Minimal Physiologically-Based Pharmacokinetic Model to Simulate Lung Exposure in Humans Following Oral Administration of Ivermectin for COVID-19 Drug Repurposing. *J Pharm Sci* **2020**; 109:3574–3578.
14. Campillo JT, Boussinesq M, Bertout S, Faillie J-L, Chesnais CB. Serious adverse reactions associated with ivermectin: A systematic pharmacovigilance study in sub-Saharan Africa and in the rest of the World. *PLoS Negl Trop Dis* **2021**; 15:e0009354.
15. Wagstaff KM, Sivakumaran H, Heaton SM, Harrich D, Jans DA. Ivermectin is a specific inhibitor of importin α/β -mediated nuclear import able to inhibit replication of HIV-1 and dengue virus. *Biochem J* **2012**; 443:851–856.
16. Hamming I, Timens W, Bulthuis MLC, Lely AT, Navis GJ, van Goor H. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. *J Pathol* **2004**; 203:631–637.

17. Zhang H, Penninger JM, Li Y, Zhong N, Slutsky AS. Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. *Intensive Care Med* **2020**; :1–5.
18. Yang SNY, Atkinson SC, Wang C, et al. The broad spectrum antiviral ivermectin targets the host nuclear transport importin α/β 1 heterodimer. *Antiviral Res* **2020**; 177:104760.
19. Jans DA, Wagstaff KM. Ivermectin as a Broad-Spectrum Host-Directed Antiviral: The Real Deal? *Cells* **2020**; 9.
20. Krause RM, Buisson B, Bertrand S, et al. Ivermectin: a positive allosteric effector of the α 7 neuronal nicotinic acetylcholine receptor. *Mol Pharmacol* **1998**; 53:283–294.
21. Changeux J-P, Amoura Z, Rey FA, Miyara M. A nicotinic hypothesis for Covid-19 with preventive and therapeutic implications. *Comptes Rendus Biologies* **2020**; 343:33–39.
22. Awadzi K, Opoku NO, Attah SK, Lazdins-Helds J, Kuesel AC. A randomized, single-ascending-dose, ivermectin-controlled, double-blind study of moxidectin in *Onchocerca volvulus* infection. *PLoS Negl Trop Dis* **2014**; 8:e2953.
23. Kuesel AC. Research for new drugs for elimination of onchocerciasis in Africa. *Int J Parasitol Drugs Drug Resist* **2016**; 6:272–286.
24. Opoku NO, Bakajika DK, Kanza EM, et al. Single dose moxidectin versus ivermectin for *Onchocerca volvulus* infection in Ghana, Liberia, and the Democratic Republic of the Congo: a randomised, controlled, double-blind phase 3 trial. *Lancet* **2018**; 392:1207–1216.
25. Pérez R, Cabezas I, García M, et al. Comparison of the pharmacokinetics of moxidectin (Equest) and ivermectin (Eqvalan) in horses. *J Vet Pharmacol Ther* **1999**; 22:174–180.

- 1 26. Al-Azzam SI, Fleckenstein L, Cheng K-J, Dzimianski MT, McCall JW. Comparison of
2 the pharmacokinetics of moxidectin and ivermectin after oral administration to beagle dogs.
3 *Biopharm Drug Dispos* **2007**; 28:431–438.
- 4 27. Corman VM, Landt O, Kaiser M, et al. Detection of 2019 novel coronavirus (2019-nCoV)
5 by real-time RT-PCR. *Euro Surveill* **2020**; 25(3): 2000045
- 6 28. Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the
7 recently emerged novel coronavirus (2019-nCoV) in vitro. *Cell Research* **2020**; 30:269–271.1
- 8 29. Choy K-T, Wong AY-L, Kaewpreedee P, et al. Remdesivir, lopinavir, emetine, and
9 homoharringtonine inhibit SARS-CoV-2 replication in vitro. *Antiviral Research* **2020**;
10 178:104786.
- 11 30. Zhang P, Ni H, Zhang Y, et al. Ivermectin confers its cytotoxic effects by inducing
12 AMPK/mTOR-mediated autophagy and DNA damage. *Chemosphere* **2020**; 259:127448.
- 13 31. Zhang P, Zhang Y, Liu K, et al. Ivermectin induces cell cycle arrest and apoptosis of
14 HeLa cells via mitochondrial pathway. *Cell Proliferation* **2019**; 52:e12543.
- 15 32. Shang J, Wan Y, Luo C, et al. Cell entry mechanisms of SARS-CoV-2. *PNAS* **2020**;
16 117:11727–11734.
- 17 33. Murgolo N, Therien AG, Howell B, et al. SARS-CoV-2 tropism, entry, replication, and
18 propagation: Considerations for drug discovery and development. *PLoS Pathog* **2021**;
19 17:e1009225.
- 20 34. Hoffmann M, Mösbauer K, Hofmann-Winkler H, et al. Chloroquine does not inhibit
21 infection of human lung cells with SARS-CoV-2. *Nature* **2020**; 585:588–590.

35. Buchrieser J, Dufloo J, Hubert M, et al. Syncytia formation by SARS-CoV-2-infected cells. *The EMBO Journal* **2020**; 39:e106267.
36. Swann H, Sharma A, Preece B, et al. Minimal system for assembly of SARS-CoV-2 virus like particles. *Scientific Reports* **2020**; 10:21877.
37. Xu R, Shi M, Li J, Song P, Li N. Construction of SARS-CoV-2 Virus-Like Particles by Mammalian Expression System. *Front Bioeng Biotechnol* **2020**; 8:862.
38. Plescia CB, David EA, Patra D, et al. SARS-CoV-2 viral budding and entry can be modeled using BSL-2 level virus-like particles. *J Biol Chem* **2020**;
39. Boson B, Legros V, Zhou B, et al. The SARS-CoV-2 envelope and membrane proteins modulate maturation and retention of the spike protein, allowing assembly of virus-like particles. *J Biol Chem* **2020**; 296:100111.
40. Zhu Y, Chidekel A, Shaffer TH. Cultured human airway epithelial cells (calu-3): a model of human respiratory function, structure, and inflammatory responses. *Crit Care Res Pract* **2010**; 2010.
41. Arshad U, Pertinez H, Box H, et al. Prioritization of Anti-SARS-Cov-2 Drug Repurposing Opportunities Based on Plasma and Target Site Concentrations Derived from their Established Human Pharmacokinetics. *Clin Pharmacol Ther* **2020**; 108:775–790.
42. Alvinerie M, Escudero E, Sutra J-F, Eeckhoutte C, Galtier P. The pharmacokinetics of moxidectin after oral and subcutaneous administration to sheep. *Vet Res*, **1998**; 29(2):113-118
43. Lifschitz, Virkel, Imperiale, et al. Moxidectin in cattle: correlation between plasma and target tissues disposition. *J Vet Pharmacol Ther* **1999**; 22:266–273.

44. Korth-Bradley JM, Parks V, Chalon S, et al. The effect of a high-fat breakfast on the pharmacokinetics of moxidectin in healthy male subjects: a randomized phase I trial. *Am J Trop Med Hyg* **2012**; 86:122–125.
45. Cotreau MM, Warren S, Ryan JL, et al. The antiparasitic moxidectin: safety, tolerability, and pharmacokinetics in humans. *J Clin Pharmacol* **2003**; 43:1108–1115.
46. Korth-Bradley JM, Parks V, Chalon S, et al. Excretion of moxidectin into breast milk and pharmacokinetics in healthy lactating women. *Antimicrob Agents Chemother* **2011**; 55:5200–5204.
47. Korth-Bradley JM, Parks V, Patat A, Matschke K, Mayer P, Fleckenstein L. Relative Bioavailability of Liquid and Tablet Formulations of the Antiparasitic Moxidectin. *Clin Pharmacol Drug Dev* **2012**; 1:32–37.
48. Korth-Bradley JM, Parks V, Wagner F, et al. Effect of moxidectin on CYP3A4 activity as evaluated by oral midazolam pharmacokinetics in healthy subjects. *Clin Pharmacol Drug Dev* **2014**; 3:151–157.
49. Vercruysse J, Rew RS, editors. *Macrocyclic lactones in antiparasitic therapy*. Oxon, UK ; New York, NY: CABI Pub, 2002.
50. Sarasola P, Jernigan AD, Walker DK, Castledine J, Smith DG, Rowan TG. Pharmacokinetics of selamectin following intravenous, oral and topical administration in cats and dogs. *J Vet Pharmacol Ther* **2002**; 25:265–272.
51. Toutain PL, Upson DW, Terhune TN, McKenzie ME. Comparative pharmacokinetics of doramectin and ivermectin in cattle. *Vet Parasitol* **1997**; 72:3–8.

52. Pérez R, Cabezas I, Godoy C, et al. Pharmacokinetics of Doramectin and Ivermectin After Oral Administration in Horses*. The Veterinary Journal **2002**; 163:161–167.
53. Holmstrom SD, Totten ML, Newhall KB, Qiao M, Riggs KL. Pharmacokinetics of spinosad and milbemycin oxime administered in combination and separately per os to dogs. J Vet Pharmacol Ther **2012**; 35:351–364.
54. Ide J, Okasaki T, Ono M. Milbemycin : Discovery and Development. Annu Rep Sankyo Res Lab. 1993; :1–98.
55. Gardon J, Gardon-Wendel N, Demanga-Ngangue null, Kamgno J, Chippaux JP, Boussinesq M. Serious reactions after mass treatment of onchocerciasis with ivermectin in an area endemic for Loa loa infection. Lancet **1997**; 350:18–22.
56. Baudou E, Lespine A, Durrieu G, et al. Serious Ivermectin Toxicity and Human ABCB1 Nonsense Mutations. New England Journal of Medicine **2020**; 383:787–789.
57. Bishop BF, Bruce CI, Evans NA, et al. Selamectin: a novel broad-spectrum endectocide for dogs and cats. Veterinary Parasitology **2000**; 91:163–176.
58. El-Saber Batiha G, Alqahtani A, Ilesanmi OB, et al. Avermectin Derivatives, Pharmacokinetics, Therapeutic and Toxic Dosages, Mechanism of Action, and Their Biological Effects. Pharmaceuticals (Basel) **2020**; 13.
59. Merola VM, Eubig PA. Toxicology of avermectins and milbemycins (macrocylic lactones) and the role of P-glycoprotein in dogs and cats. Vet Clin North Am Small Anim Pract **2012**; 42:313–333, vii.
60. Prichard R, Ménez C, Lespine A. Moxidectin and the avermectins: Consanguinity but not

identity. *Int J Parasitol Drugs Drug Resist* **2012**; 2:134–153.

61. WHO Solidarity Trial Consortium, Pan H, Peto R, et al. Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results. *N Engl J Med* **2020**;

62. Chaccour C, Abizanda G, Irigoyen-Barrio Á, et al. Nebulized ivermectin for COVID-19 and other respiratory diseases, a proof of concept, dose-ranging study in rats. *Sci Rep* **2020**; 10:17073.

63. Nilima Dinesh Kumar, Bram M. ter Ellen, Ellen M. Bouma, Berit Troost, Denise P. I. van de Pol, Heidi H. van der Ende-Metselaar, Djoke van Gosliga, Leonie Apperloo, Orestes A. Carpaij, Maarten van den Berge, Martijn C. Nawijn, Ymkje Stienstra, Izabela A Rodenhuis-Zybert, Jolanda M. Smit. Moxidectin and ivermectin inhibit SARS-CoV-2 replication in Vero E6 cells but not in human primary airway epithelium cells. *AAC* 11 Octobre **2021** ; 01543-21.

FIGURES

A

B

Figure 1. Antiviral and cytotoxic activities of selected compounds against SARS-CoV-2 infection in Vero E6 cells. (A) Structure of avermectins and milbemycins drugs used in this study.

(B) Vero E6 cells were infected with SARS-CoV-2 at a MOI of 0.01 with 0.05, 0.1, 0.25, 0.5, 1, 2.5, 5, 10 and 50 μ M of the indicated compounds and incubated for 72 hours. The cytotoxicity of the drugs to Vero E6 cells was measured by MTS assay. Inhibition of virus replication was either quantified by MTS (black) or ToxGlo (purple) assays. The left and right Y-axes of the graphs stand for mean % inhibition vs. DMSO control and mean % cell survival (red), respectively. Data points are mean values and bars are the standard deviation of experiments performed in duplicate.

a

b

Figure 2. Antiviral and cytotoxic activities of selected compounds against SARS-CoV-2 infection in A549-hACE2 cells. A549-hACE2 were infected with SARS-CoV-2 at a MOI of 0.01

with 0.025, 0.05, 0.1, 0.25, 0.5, 1, 2.5, 5, 10 and 25 μ M of the indicated compounds and incubated for 72 hours. **(a)** Cytotoxic activity is shown in red curves and antiviral activity is shown in the black curves. The cytotoxicity of the drugs to A549-hACE2 cells was measured by MTS assay. Inhibition of virus replication was quantified by ToxGlo assay. The left and right Y-axes of the graphs stand for mean % inhibition vs. DMSO control (black) and mean % cell survival (red), respectively. **(b)** Viral RNA quantification by RT-qPCR from viral supernatant at 72 hours. Data points are mean values and bars are the standard deviation of three independent experiments performed in duplicate.

Figure 3. Antiviral and cytotoxic activities of selected compounds against SARS-CoV-2 infection in Calu-3 cells. Calu-3 cells were infected with SARS-CoV-2 at a MOI of 0.01 with 0.025, 0.05, 0.1, 0.25, 0.5, 1, 2.5, 5, 10 and 25 μM of the indicated compounds and incubated for 72 hours. The cytotoxicity of the drugs to Calu-3 cells was measured by MTS assay. Inhibition of virus replication was quantified through viral RNA quantification by RT-qPCR from viral supernatant at 72 hours. Cytotoxic activity is shown in red curves and the percentage of viral genome copies against the infected control is shown in the black curves. Data points are mean values and bars are the standard deviation of three independent experiments performed in duplicate.

Figure 4. Cell monitoring and quantification of MOX and IVM antiviral activities. A549-hACE2 cells were infected with SARS-CoV-2 at MOI 0.01 in presence of MOX (4 μM) or IVM (4 μM). A549-hACE2 cells were fixed at 48h post infection, stained with DAPI and processed for immunofluorescence confocal microscopy using a SARS membrane protein anti-M rabbit antibody and a secondary antibody Alexa Fluor 568. (a) Viral RNA quantification from cell supernatant at 48 hpi. (b) Epifluorescence images of mock (NI) and infected cells (INF), the cells nuclei are shown in blue and the M protein in red. The arrow points towards giant cells containing multiple nuclei. The number of cell fusions observed in mock and in absence or presence of drugs in infected cells has been quantified by measuring the number of polynuclei cells (c) or the surface of nuclei in the cell population (d). In (d) p values are indicated and were computed by using two-sided independent t tests and comparing the results to those for the untreated sample. (e-f) Changes in total intensity of virus (αM) per cell of SARS-CoV-2 infected A549-hACE2 cells with and without drugs IVM and MOX. (e) Images for intensity of virus (αM) with or without IVM and MOX 48

hpi (f) Data for virus intensity per cell with or without drugs. A number of $40 < n < 50$ cells were analyzed from at least 3 independent experiments.

Table 1: Antiviral activities of selected compounds against SARS-CoV-2 in Vero E6 cells, A549-hACE2 cells and Calu-3 cells. EC50 MTS, EC50 ToxGlo and EC50 RT-qPCR correspond to the 50% effective concentration determined respectively by CPE reduction, using MTS or ToxGlo assay, or RT-qPCR. CC50: 50% cytotoxic concentration, SI: Selectivity index.

COMPOUND	EC50 (μM) MTS	EC50 (μM) ToxGlo	EC50 (μM) RT-qPCR	CC50 (μM)	SI
VERO E6 cells					
REMDESIVIR	0.55	1		> 50	>49
MOXIDECTIN	5.3	3.5		8.8	1.66
DORAMECTIN	2.4	1.1		8.3	3.45
SELAMECTIN	3.9	2.3		8.3	2.1
IVERMECTIN	3.6	3		8	2.2
MILBEMYCIN	3.8	2.6		7.8	2.05
A549 hACE2 cells					
REMDESIVIR	0.15		0.31	>> 10	> 30
MOXIDECTIN	1.3		1.27	6.2	4.7
IVERMECTIN	2.1		2.36	6.2	2.8
MILBEMYCIN	2.7		2.8	6.1	2.2
Calu-3 cells					
REMDESIVIR			0.35	>> 25	> 70
MOXIDECTIN			5.55	26	4.7
IVERMECTIN			3.36	22	5
MILBEMYCIN			6.78	23	3.3

Supplementary Figures

Figure S1. Principle of the antiviral drug screening method.

(a) Example of the cytopathic effect (CPE) of SARS-CoV-2 on confluent VeroE6 cells (well of a 96-well plate) after 3 days of infection (at MOI = 0.01) versus non infected cells (NI) as observed using an EVOS microscope with a 4x objective; (b) Example cell viability (using MTS) in 96 well plates of infected (orange) and non infected (brown) cells; (c) Example of antiviral curve deduced: quantification corresponding to the cell toxicity using MTS (blue line) and the % of inhibition deduced from viral CPE after remdesivir cell treatment (red line).